Section Arrow
ADAG.NASDAQ
- Adagene
Quotes are at least 15-min delayed:2026/09/08 16:04 EDT
After Hours
Last
 --
-- (--)
Bid
3.45
Ask
3.48
High -- 
Low -- 
Volume -- 
Regular Hours (Closed)
Last
 3.46
-0.12 (-3.35%)
Day High 
3.61 
Prev. Close
3.58 
1-M High
4.2392 
Volume 
186.23K 
Bid
3.45
Ask
3.48
Day Low
3.45 
Open
3.55 
1-M Low
3.42 
Market Cap 
240.37M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 3.73 
20-SMA 3.83 
50-SMA 3.84 
52-W High 4.85 
52-W Low 1.3 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.38/-0.44
Enterprise Value
241.56M
Balance Sheet
Book Value Per Share
1.33
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
7.67M
Operating Revenue Per Share
0.34
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
PDSBPDS Biotechnology Corp0.3097+0.0897+40.77%-- 
After Hours -- -- --
ATAIAtaiBeckley Inc7.245-0.145-1.96%-- 
After Hours -- -- --
ROIVRoivant Sciences Ltd41.64+6.71+19.21%-- 
After Hours -- -- --
DYNDyne Therapeutics20.675-3.605-14.85%-- 
After Hours -- -- --
RXRXRecursion Pharmaceuticals3.445-0.185-5.10%-- 
After Hours -- -- --
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.